We also found SOX2 promotes AKT phosphorylation in bladder cancer cells by inducing IGF2 and IGF1R expression and suppressing IGFBP1. We further characterized the potential of IGF1R signaling as a biomarker and therapeutic target in treating bladder cancer. Here, IGF2 is linked to urinary bladder cancer.